Cyberliver reports a positive pilot study of AlcoChange, a patented Smartphone Tool and Behavioural Intervention Platform to Reduce Alcohol Consumption in Alcohol-Related Liver Disease. The data from this study is very exciting and shows that we can potentially find new treatments using digital technologies for treating liver disease to reduce deaths and improve quality of life.
The poster is entitled: �AlcoChange: A Pilot Study of a Smartphone Tool to Reduce Alcohol Consumption in Alcohol-Related Liver Disease (Poster #1398)� will be presented on Sunday, November 11 2018, between 8:00 AM and 5:30 PM at Hall C � Poster Hall.
Dr. Gautam Mehta, Clinical Lead of the study, Consultant and Senior Lecturer in Hepatology at Royal Free Hospital said, �We are delighted to be presenting this study at The Liver Meeting 2018. The data demonstrate the potential of digital tools like AlcoChange to help manage alcohol-related liver disease (ARLD).� The AlcoChange clinical study, which ran from spring 2015 to end of 2017 at Royal Free London NHS Trust, supported by The Health Foundation and led by Prof. Kevin Moore and Dr. Gautam Mehta, clearly demonstrated that a smartphone app/breathalyzer can be used for self-monitoring and for Behavior Change Interventions (BCIs) in patients with ARLD, with a clear "dose response" amongst compliant patients. �Smartphone apps are a scalable intervention to help maintain abstinence in ARLD.�
Commenting on the study, Prof. Rajiv Jalan, Clinician Scientist, Prof. of Hepatology, Head of Liver Failure group at UCL said, �The data from this study is very exciting and shows that we can potentially find new treatments using digital technologies for treating liver disease to reduce deaths and improve quality of life.�
About Cyberliver:
Cyberliver is a company that focuses on delivering cutting edge solutions for liver care via use of innovative technology, based out of London, England, UK.
About AlcoChange:
AlcoChange is a patented Smartphone App/Breathalyzer platform, allows the monitoring of craving, alcohol consumption and breath alcohol, and provides motivational messaging in response to patient triggers.
For AlcoChange and Cyberliver Contact:
Ravi Kumar, [email protected]
First Floor, Burnells, 5 Garland Road, Stanmore, Middlesex, HA7 1NR, United Kingdom
More from miscw.com
PMQ’s ‘FabriX 2023 – Digital Fashion Roadshow’: Bringing the pioneering digital fashion experience to London and Paris Fashion Week First-to-try by a few can’t-be-missed next-gen KOLs, a moment of Fashion meets Future!
QuestCap and MTJR Partnership Signs Sales Agreement for 500,000�Antibody Tests- City of Austin Partners with NTT to Accelerate Smart City Technologies
- The Relevance of Privacy in the Digital Age (Research by SOVA LTD)
